What is ALMS's current stock price?

ALMS (Alumis Inc. Common Stock) is currently trading at $22.02 with a market cap of $2.72B.

What sector is Alumis Inc. Common Stock in?

Alumis Inc. Common Stock (ALMS) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is ALMS a good stock to buy?

Analysts have a Buy consensus on ALMS with a price target of $39.33. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

ALMS Alumis Inc. Common Stock

Healthcare

$22.02-0.68%ClosedMarket Cap: $2.72B

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

4.86

P/S

323.49

EV/EBITDA

-6.29

DCF Value

$1.08

FCF Yield

-13.9%

Div Yield

0.0%

Margins & Returns

Gross Margin

89.6%

Operating Margin

-5364.0%

Net Margin

-2825.7%

ROE

-54.6%

ROA

-35.4%

ROIC

-71.9%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$1.7M	$-93.1M	$—
Q4 null	$1.9M	$-92.9M	$—
FY null	$24.1M	$-243.3M	$—
Q3 null	$2.1M	$-110.8M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$39.33

Target (Median)

$39.00

Target Range

$25.00 - $51.00

1 Strong Buy10 Buy1 Hold0 Sell0 Strong Sell

Chardan CapitalBuy

2026-05-19

HC Wainwright & Co.Neutral

2026-05-15

Wells FargoOverweight

2026-05-15

GuggenheimBuy

2026-05-15

Chardan CapitalBuy

2026-03-30

Trading Activity

Insider Trades

View All

Tananbaum James B.director, 10 percent owner:

SellFri Apr 03

Tananbaum James B.director, 10 percent owner:

SellFri Apr 03

Foresite Labs, LLC10 percent owner

SellFri Apr 03

Foresite Labs, LLC10 percent owner

SellFri Apr 03

Foresite Capital Management VI LLC10 percent owner

SellFri Apr 03

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

-0.29

Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. It develops ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis, systemic lupus erythematosus, and non-infectious uveitis; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. The company was incorporated in 2021 and is headquartered in South San Francisco, California.

Peers